LIFECORE BIOMEDICAL, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
LIFECORE BIOMEDICAL, INC. (LFCR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$3.29 million for the 3-month period ending 2017-08-27, per its 10-Q filed 2017-09-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-03-15
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-08-27 was -$3.29M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-05-28 was -$15.60M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-02-26 was -$4.69M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-11-27 was -$2.60M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$25.01M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$41.59M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$34.44M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$13.34M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-08-27 | -$3.29M 10-Q · filed 2017-09-28 | -$18.89M derived: sum of 2 quarters · filed 2018-03-15 | -$23.57M derived: sum of 3 quarters · filed 2018-03-15 | -$26.18M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-05-28 | -$15.60M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | -$20.29M derived: sum of 2 quarters · filed 2018-03-15 | -$22.89M derived: sum of 3 quarters · filed 2018-03-15 | -$25.01M 10-K/A · filed 2018-03-15 |
| 2017-02-26 | -$4.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-07 | -$7.29M derived: sum of 2 quarters · filed 2017-04-07 | -$9.41M 10-Q · filed 2017-04-07 | -$24.12M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-11-27 | -$2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-01-05 | -$4.72M 10-Q · filed 2017-01-05 | -$19.43M derived: sum of 3 quarters · filed 2018-03-15 | -$30.35M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-08-28 | -$2.12M 10-Q · filed 2017-09-28 | -$16.83M derived: sum of 2 quarters · filed 2018-03-15 | -$27.75M derived: sum of 3 quarters · filed 2018-03-15 | -$40.32M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-05-29 | -$14.71M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | -$25.63M derived: sum of 2 quarters · filed 2018-03-15 | -$38.19M derived: sum of 3 quarters · filed 2018-03-15 | -$41.59M 10-K/A · filed 2018-03-15 |
| 2016-02-28 | -$10.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-07 | -$23.49M derived: sum of 2 quarters · filed 2017-04-07 | -$26.88M 10-Q · filed 2017-04-07 | -$34.04M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-11-29 | -$12.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-01-05 | -$15.96M 10-Q · filed 2017-01-05 | -$23.12M derived: sum of 3 quarters · filed 2018-03-15 | -$25.27M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-08-30 | -$3.40M 10-Q · filed 2016-09-29 | -$10.56M derived: sum of 2 quarters · filed 2018-03-15 | -$12.70M derived: sum of 3 quarters · filed 2018-03-15 | -$22.74M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-05-31 | -$7.16M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | -$9.30M derived: sum of 2 quarters · filed 2018-03-15 | -$19.34M derived: sum of 3 quarters · filed 2018-03-15 | -$34.44M 10-K/A · filed 2018-03-15 |
| 2015-03-01 | -$2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | -$12.18M derived: sum of 2 quarters · filed 2016-03-30 | -$27.28M 10-Q · filed 2016-03-30 | -$31.97M derived: sum of 4 quarters · filed 2016-08-01 |
| 2014-11-30 | -$10.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-07 | -$25.14M 10-Q · filed 2016-01-07 | -$29.83M derived: sum of 3 quarters · filed 2016-08-01 | -$32.34M derived: sum of 4 quarters · filed 2016-08-01 |
| 2014-08-31 | -$15.10M 10-Q · filed 2015-10-01 | -$19.79M derived: sum of 2 quarters · filed 2016-08-01 | -$22.30M derived: sum of 3 quarters · filed 2016-08-01 | -$24.34M derived: sum of 4 quarters · filed 2016-08-01 |
| 2014-05-25 | -$4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | -$7.21M derived: sum of 2 quarters · filed 2016-08-01 | -$9.24M derived: sum of 3 quarters · filed 2016-08-01 | -$13.34M 10-K · filed 2016-08-01 |
| 2014-02-23 | -$2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-02 | -$4.55M derived: sum of 2 quarters · filed 2015-04-02 | -$8.65M 10-Q · filed 2015-04-02 | |
| 2013-11-24 | -$2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-09 | -$6.14M 10-Q · filed 2015-01-09 | ||
| 2013-08-25 | -$4.10M 10-Q · filed 2014-10-08 | |||
| 2013-05-26 | -$10.42M 10-K · filed 2015-07-31 | |||
| 2012-05-27 | -$44.07M 10-K · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |